Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.

Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Evaluation of the oncolytic property of recombinant Newcastle disease virus strain R2B in 4T1 and B16-F10 cells in-vitro

Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy

Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors

Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications

Recombinant Newcastle disease virus immunotherapy drives oncolytic effects and durable systemic antitumor immunity

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma

A phase I study to evaluate the safety and effectiveness of neoantigen-based personalized dendritic cell vaccine in patients with advanced solid tumors.